Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells
Petra Gener(CIBBIM-Nanomedicine), Simó Schwartz(CIBBIM-Nanomedicine), Joan Sayós(Beth Israel Deaconess Medical Center), Guillem Romero Sabat(Vall d'Hebron Institut de Recerca), Ibane Abasolo(Unknown), Alexandra Arranja(University of Lisbon), Diego Arango(Unknown), Núria Bergadà Fort(Vall d'Hebron Institut de Recerca), Yolanda Fernández(CIBBIM-Nanomedicine), Mafalda Videira(University of Lisbon), Rafael Miñana Prieto(Vall d'Hebron Institut de Recerca), Diana Rafael(University of Lisbon)
Cited by 85
Related Papers
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM
|Nature|1998|942
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
|British Journal of Cancer|2004|275
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
|Advanced Drug Delivery Reviews|2013|237
Immune system targeting by biodegradable nanoparticles for cancer vaccines
|Journal of Controlled Release|2013|229
Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles
|Journal of drug targeting|2002|210